These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34513918)

  • 1. Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level
    Yang Y; Lv W; Xu S; Shi F; Shan A; Wang J
    Front Mol Biosci; 2021; 8():567327. PubMed ID: 34513918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
    Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
    [No Abstract]   [Full Text] [Related]  

  • 3. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
    Wang J; Shi F; Shan A
    Front Oncol; 2022; 12():946967. PubMed ID: 36276141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.
    Wang J; Shan A; Shi F; Zheng Q
    Front Med (Lausanne); 2023; 10():1044402. PubMed ID: 37928479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma.
    Wang J; Xu S; Lv W; Shi F; Mei S; Shan A; Xu J; Yang Y
    Cancer Med; 2020 Aug; 9(16):5940-5947. PubMed ID: 32583596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
    Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
    Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
    [No Abstract]   [Full Text] [Related]  

  • 7. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
    Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
    Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BDKRB2 is a novel EMT-related biomarker and predicts poor survival in glioma.
    Yang Y; Wang J; Shi F; Shan A; Xu S; Lv W
    Aging (Albany NY); 2021 Mar; 13(5):7499-7516. PubMed ID: 33686021
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yang Y; Wang J; Xu S; Lv W; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):9-19. PubMed ID: 33552590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
    Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
    CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
    Long S; Li M; Liu J; Yang Y; Li G
    Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
    Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
    Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
    Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
    Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and Clinical Features of
    Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
    Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
    Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
    Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characterization and Prognostic Value of TPM4 and Its Correlation with Epithelial-Mesenchymal Transition in Glioma.
    Wang J; Yang Y; Du B
    Brain Sci; 2022 Aug; 12(9):. PubMed ID: 36138856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
    Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
    Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.
    Yang Y; Wang J; Xu S; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):67-75. PubMed ID: 33623713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
    Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
    Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.